Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
Orencia, abatacept (ONO-4164IV)
Also known as: CTLA4-Ig (formerly BMS-188667IV)
print preview
bookmark
share with colleague
General Information
Company
Bristol-Myers Squibb Co.
Description
CTLA-4-Ig fusion protein
Molecular Target
CD80 (B7-1)
;
CD86 (B7-2)
Mechanism of Action
Immune modulation
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Disease Category
Standard Indication
Indication Details
Partners
Milestones
Latest Stage of Development
More
Archive Items are loading
Set Email Alert
dummy